ViGenCell Inc.
ViGenCell Inc. provides immune cell therapy in South Korea. It develops ViTier, an antigen-specific killer T cell therapy, such as VT-EBV-N for NK/T Lymphoma indications and VT-Tri(1)-A for AML indications; ViMedier, a cord blood-derived myeloid suppressor cell therapy, including VM-GD for GvHD indications and VM-AD for atopic dermatitis indications; and ViRanger, an off-the-shelf allogenic unive… Read more
Market Cap & Net Worth: ViGenCell Inc. (308080)
ViGenCell Inc. (KQ:308080) has a market capitalization of $81.42 Million (₩119.22 Billion) as of March 19, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #20085 globally and #854 in its home market, demonstrating a 10.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ViGenCell Inc.'s stock price ₩5830.00 by its total outstanding shares 20449100 (20.45 Million).
ViGenCell Inc. Market Cap History: 2021 to 2026
ViGenCell Inc.'s market capitalization history from 2021 to 2026. Data shows change from $514.65 Million to $81.42 Million (-39.90% CAGR).
Index Memberships
ViGenCell Inc. is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$167.85 Billion | 0.04% | #374 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$167.85 Billion | 0.04% | #374 of 1384 |
Weight: ViGenCell Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
ViGenCell Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ViGenCell Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.13x
ViGenCell Inc.'s market cap is 0.13 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2024 | $34.92 Million | $278.95 Million | -$14.06 Billion | 0.13x | N/A |
Competitor Companies of 308080 by Market Capitalization
Companies near ViGenCell Inc. in the global market cap rankings as of March 19, 2026.
Key companies related to ViGenCell Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
ViGenCell Inc. Historical Marketcap From 2021 to 2026
Between 2021 and today, ViGenCell Inc.'s market cap moved from $514.65 Million to $ 81.42 Million, with a yearly change of -39.90%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩81.42 Million | -40.21% |
| 2025 | ₩136.17 Million | +290.00% |
| 2024 | ₩34.92 Million | -57.26% |
| 2023 | ₩81.70 Million | -17.84% |
| 2022 | ₩99.44 Million | -80.68% |
| 2021 | ₩514.65 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of ViGenCell Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $81.42 Million USD |
| MoneyControl | $81.42 Million USD |
| MarketWatch | $81.42 Million USD |
| marketcap.company | $81.42 Million USD |
| Reuters | $81.42 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.